Table 3.
Systemic concentrations of L-arginine/NO pathway metabolites in CRC.
| Metabolite | Controls (n = 54) | Adenomas (n = 8) | CRC (n = 137) | p-Value |
|---|---|---|---|---|
| Arg [µM] | 131.8 (110–147) | 175.8 (133–212) | 140.6 (106–174) | 0.084 4 |
| Cit [µM] | 58.7 (42–110) 1 | 52.1 (37–58) | 46.6 (36–61) 2 | 0.002 4 |
| ADMA [µM] | 0.52 (0.46–0.48) 1 | 0.54 (0.51–0.62) | 0.58 (0.48–0.67) 2 | 0.013 4 |
| SDMA [µM] | 0.42 (0.37–0.49) 1,3 | 0.62 (0.50–0.75) 2 | 0.57 (0.47–0.69) 2 | <0.00001 4 |
| DMA [µM] | 48.4 (39–59) 3 | 84.2 (78–88) 1,3 | 63.2 (35–77) 3 | <0.001 4 |
Data presented as medians with an interquartile range. Arg: Arginine; Cit: Citrulline; ADMA: Asymmetric dimethylarginine; SDMA: Symmetric dimethylarginine; DMA: Dimethylamine; CRC: Colorectal cancer; 1 significantly different from CRC; 2 significantly different from controls; 3 significantly different from adenomas; 4 Kruskal-Wallis H test.